ACT Capital Management’s Nektar Therapeutics NKTR Stock Holding History

ACT Capital Management’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.23M	Buy	89,300 +18,400	+26%	+$1.35M	4.07%	9
2026 Q1	$5.1M	Buy	70,900 +19,700	+38%	+$1.12M	4.01%	10
2025 Q4	$2.16M	Buy	+51,200	New	+$2.87M	1.75%	18
2022 Q2	–	Sell	-400	Closed	-$32K	–	89
2022 Q1	$32K	Sell	400 -2,667	-87%	-$395K	0.03%	81
2021 Q4	$621K	Sell	3,067 -7,700	-72%	-$1.67M	0.45%	41
2021 Q3	$2.9M	Hold	10,767	–	–	1.5%	13
2021 Q2	$2.77M	Buy	+10,767	New	+$2.98M	1.42%	14

Other funds holding NKTR

Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

EMFAT

Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.85B AUM 140.52% 1-Year Est. Return

BCM

Bronte Capital Management Bondi Junction, Australia $931M AUM 47.97% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

MAP

Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return

FMI

F/M Investments Washington, District of Columbia $1.97B AUM 30.33% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return

EAM

Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return

ACT Capital Management's NKTR Position: Q2 2026 in Review

ACT Capital Management increased its Nektar Therapeutics (NKTR) stake by 26% in Q2 2026, buying an estimated $1.35M and bringing the position to 89,300 shares worth $6.23M. The position accounts for 4.07% of the portfolio, ranked #9.

ACT Capital Management first reported a position in NKTR in Q2 2021 and has held it in 7 quarters since. 43 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

ACT Capital Management held 89,300 shares of Nektar Therapeutics worth $6.23M as of Q2 2026.
ACT Capital Management bought 18,400 Nektar Therapeutics shares in Q2 2026, an estimated $1.35M.
Nektar Therapeutics made up 4.07% of ACT Capital Management's portfolio in Q2 2026, its #9 holding.
ACT Capital Management first reported a position in Nektar Therapeutics in Q2 2021 and has held it in 7 quarters since.
43 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on ACT Capital Management's 13F filing for Q2 2026, filed 29 Jul 2026.